- Home
- LXEO vs CHRS Comparison
LXEO vs CHRS Comparison
Compare LXEO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- CHRS
- Stock Information
- Founded
- LXEO 2017
- CHRS 2010
- Country
- LXEO United States
- CHRS United States
- Employees
- LXEO N/A
- CHRS N/A
- Industry
- LXEO
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LXEO
- CHRS Health Care
- Exchange
- LXEO Nasdaq
- CHRS Nasdaq
- Market Cap
- LXEO 93.9M
- CHRS 112.5M
- IPO Year
- LXEO 2023
- CHRS 2014
- Fundamental
- Price
- LXEO $3.91
- CHRS $0.76
- Analyst Decision
- LXEO Strong Buy
- CHRS Buy
- Analyst Count
- LXEO 5
- CHRS 3
- Target Price
- LXEO $16.60
- CHRS $4.68
- AVG Volume (30 Days)
- LXEO 697.6K
- CHRS 1.2M
- Earning Date
- LXEO 08-11-2025
- CHRS 08-07-2025
- Dividend Yield
- LXEO N/A
- CHRS N/A
- EPS Growth
- LXEO N/A
- CHRS N/A
- EPS
- LXEO N/A
- CHRS N/A
- Revenue
- LXEO N/A
- CHRS $272,251,000.00
- Revenue This Year
- LXEO N/A
- CHRS N/A
- Revenue Next Year
- LXEO N/A
- CHRS $132.69
- P/E Ratio
- LXEO N/A
- CHRS N/A
- Revenue Growth
- LXEO N/A
- CHRS 19.87
- 52 Week Low
- LXEO $1.45
- CHRS $0.66
- 52 Week High
- LXEO $19.50
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- LXEO 55.22
- CHRS 40.60
- Support Level
- LXEO $3.62
- CHRS $0.74
- Resistance Level
- LXEO $4.29
- CHRS $0.79
- Average True Range (ATR)
- LXEO 0.45
- CHRS 0.05
- MACD
- LXEO 0.04
- CHRS 0.00
- Stochastic Oscillator
- LXEO 58.68
- CHRS 12.76
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.